Rodman & Renshaw initiated coverage of Telomir Pharmaceuticals (TELO) with a Buy rating and $8 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TELO:
- Telomir Pharmaceuticals reports results from efficacy study for Telomir-1
- Telomir Highlights Positive Preclinical Results for Telomir-1 in TNBC
- Telomir Pharmaceuticals reports results from safety studies for Telomir-1
- Telomir Pharmaceuticals Reports Positive IND-Enabling Study Results
- Telomir Pharmaceuticals announces new preclinical data on Telomir-1